ClinicalTrials.gg
Status unknownNCT02826031ArtzUpdated May 4, 2017

Clinical Study of Artz in the Treatment of Knee Osteoarthritis

A Phase 4 interventional study of Sodium Hyaluronate Injection and DICL-SR in Knee Osteoarthritis, sponsored by Kunming Baker Norton Pharmaceutical Sales Co., Ltd.. Status unknown at 6 sites in China. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2017-05-04.

Sponsored by Kunming Baker Norton Pharmaceutical Sales Co., Ltd. · Phase 4, Interventional, and Treatment

The sponsor has not verified this record recently (last verified May 2017), so the status shown — last known as Recruiting — may be out of date.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 4
Study type
Interventional
Enrollment
300
Allocation
Randomized
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 18 studies testing Hyaluronic Acid in Osteoarthritis, Knee — 4 open to participants now, 4 under way, 2 of them phase 3. Hyaluronic Acid · Osteoarthritis, Knee.

Planned enrollment
Largest of 18
300 · median 55
Started
2016
with 2 others
Phase 4
6 of 18
1 open now
Registered
5th of 18
by date
Lead sponsor
1 of 18
Kunming Baker Norton Pharmaceutical Sales Co., Ltd.

Among the 18 studies testing Hyaluronic Acid in Osteoarthritis, Knee, this one has the largest planned enrollment, is one of 3 that started in 2016, is one of 6 in phase 4, and was the 5th registered.

Osteoarthritis, Knee

3,295 studies on the registry are indexed under Osteoarthritis, Knee; 624 are open to participants now.

Browse Osteoarthritis, Knee studies →

Open to participants now

4 of the 18 studies testing Hyaluronic Acid in Osteoarthritis, Knee are open now, in 4 countries. Recruiting first, the newest first:

By country, each count listing its studies:

All 4 open studies →

About Hyaluronic Acid

No approval found in the FDA or EMA files read. How studies give it is on its page →

Who these studies take

Of the 383 Osteoarthritis, Knee studies recruiting now, 177 (46%) set no upper age limit and 113 (30%) stop at 75 or younger; 19 take children under 18; 39 take healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 18 studies testing Hyaluronic Acid in Osteoarthritis, Knee, or all of them as a file.
02

Study summary

This is a multi-center, randomized, open-label, parallel-arm phase IV clinical study, for which a total of 300 patients with mild to moderate knee osteoarthritis will be enrolled. In the first 4 weeks (run-in period), the subjects will receive on-demand treatment with Diclofenac Sodium Sustained Release Tablets (DICL-SR) 75mg, quaque die(QD). After the run-in period, the subjects, if their knee pain has not worsened to a level requiring surgical treatment, will be randomized to two groups in 1:1 ratio: one group receiving Artz® via intra-articular injection (once weekly, for 5 consecutive weeks) in combination with DICL-SR 75mg,quaque die(QD), for 12 consecutive weeks on demand. The other group receiving DICL-SR 75mg alone,quaque die(QD), for 12 consecutive weeks on demand. DICL-SR 75mg quaque die(QD) may be administered to the subjects of both groups on demand as long as they have a knee pain. If the knee pain has disappeared, this drug may be withdrawn. However, if the pain occurs again and requires treatment, oral administration of DICL-SR may be resumed. A subject is allowed to withdraw from this study prematurely if unable to tolerate the adverse effects.

A total of 8 visits have been scheduled for this study, including Visit 1/screening period (Week -4), Visit 2/baseline (Week 0), Visit 3 (Week 1), Visit 4 (Week 2), Visit 5 (Week 3), Visit 6 (Week 4), Visit 7 (Week 8) and Visit 8 (Week 12).

A total of 300 subjects will participate in this study at 6 to 8 centers in China, and patient enrollment is expected to take up to 12 months.

03

Conditions studied

  • Knee Osteoarthritis

Keywords

  • Sodium Hyaluronate
  • mild to moderate knee osteoarthritis
04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  1. Adult Chinese subjects, at age≥18, either gender, diagnosed with osteoarthritis of the target knee and Kellgren-Lawrence (KL) classification Grade 1\~3, as evidenced by X-ray examination in the last 3 months (mild to moderate narrowing of joint space and / or marked osteophytes of tibiofemoral joint space)
  2. Persist pain of the target knee after exercise, weight loss and physical therapy;
  3. A baseline WOMAC A1 score for the target knee rated at 40-90mm (moderate to severe walk-associated pain) on 100mm Visual analogue scale(VAS); Able to understand and sign the Form (ICF) that has already been approved by the Independent Ethics Committee (IEC) Note: the informed consent may also be given by the duly authorized representative of the subject.

Exclusion criteria

Exclusion Criteria:

  1. A diagnosis of bilateral knee osteoarthritis;
  2. (requiring surgery) valgus or varus deformity of the knee joint, ligamentous laxity or unstable meniscus;
  3. Complicated by inflammation or any other disease /condition (e.g., rheumatic arthritis, metabolic bone disease, psoriasis, gout, pseudogout, chondrocalcinosis, etc.) that may affect the knee joint;
  4. A history of septicemia, clinically considered sub-acute infection of the target knee joint;
  5. A history of surgery on the target knee (in the last 6 months);
  6. A history of asthma, urticaria or allergy after use of aspirin or other non-steroidal anti-inflammatory drugs (NSAIDs);
  7. Severe hepatic or renal disease or hepatic /renal failure;
  8. Any unscheduled surgery on the lower limb;
  9. Clinically significant lower venous or lymphatic obstruction;
  10. Clinically significant obvious exudation or inflammation of the target knee;
  11. Skin disorders or infection at the injection site;
  12. Pregnant or lactating women;
  13. Known allergy to guanylin and / or any active ingredient or of hyaluronic acid-based injection / diclofenac sodium;
  14. Treatment with any hyaluronic acid (HA) or its derivatives for the target knee within six months before this trial;
  15. Intra-articular (IA) injection of into the target knee within 3 months before this trial;
  16. Presence of any to IA injection, e.g., patients who are receiving anti-coagulation therapy or clinically have potential coagulation disorders (e.g., hepatic disease);
  17. Presence of any clinically significant disease (e.g., significant mental or nervous disorders, alcohol/drug abuse), unstable/poorly controlled diseases, or other factors, which may affect their evaluation or participation in this study in the investigator's judgment
  18. Perioperative pain associated with coronary artery bypass surgery (CABG);
  19. A history of gastrointestinal bleeding or perforation following use of NSAIDs;
  20. Presence of active gastrointestinal ulcer /bleeding, or a past history of recurrent ulcer/bleeding; Chief complaint complicated by pain beyond the target knee,
Terms in these criteria, in plain language(5)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

Excipients

The other ingredients in a medicine besides the active drug, such as fillers, colors or preservatives.

Corticosteroids (steroids)

Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.

Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.

Contraindication

A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.

05

Study design

Phase
Phase 4
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
None (open label)
Enrollment
300 participants (estimated)

Study arms

  • Experimental
    Sodium Hyaluronate Injection + DICL-SR

    Each syringe (2.5mL) contains 25mg of sodium hyaluronate, and one Artz® will be administered via intra-articular injection into the target knee at the baseline and Weeks 1, 2, 3 and 4 respectively for the combination group. From the run-in period to the end of study, both groups will receive DICL-SR 75mg, which is administered on demand for treatment of knee pain. If the knee pain is relieved or has disappeared, DICL-SR may be withdrawn. However, if the pain occurs again and requires treatment, the drug may be resumed. If a dose of 75mg daily fails to control the knee pain, it may be increased to the maximum dose 150mg daily upon the approval of the investigator, that is, 75mg bis in die(BID) daily

    Drug: Sodium Hyaluronate Injection · Drug: DICL-SR

  • Active comparator
    DICL-SR

    From the run-in period to the end of study, both groups will receive Diclofenac Sodium Sustained-release Tablets(DICL-SR) 75mg, which is administered on demand for treatment of knee pain. If the knee pain is relieved or has disappeared, DICL-SR may be withdrawn. However, if the pain occurs again and requires treatment, the drug may be resumed. If a dose of 75mg daily fails to control the knee pain, it may be increased to the maximum dose 150mg daily upon the approval of the investigator, that is, 75mg bis in die(BID daily). A subject is allowed to withdraw from this study prematurely if unable to tolerate the adverse effects.

    Drug: DICL-SR

Interventions

06

What researchers measure

Primary outcomes

  1. Compare the average daily doses (unit: pills) of the NSAID from Week9 (W9) to W12 between two groups

    Time frame: From W9 to W12 (4 weeks)

Secondary outcomes

  1. Compare the average daily doses (unit: pills) of the NSAID from W5 to W8, and W5 to W12 between two groups

    Time frame: From W5 to W8 (4 weeks), and W5 to W12 (8 weeks)

  2. Compare the changes in the average daily doses (unit: pills) of the NSAID at the 8th and 12th week from baseline between two groups.

    Time frame: At the 8th week from baseline (1 week), and at the 12th week from baseline (1 week)

  3. Compare the percentage changes in the average daily doses (unit: pills) of the NSAID at the 8th and 12th week from baseline between two groups.

    Time frame: At the 8th week from baseline (1 week), and at the 12th week from baseline (1 week)

  4. Compare the days of NSAID consumption from W5 to W8, W9 to W12, and W5 to W12 between two groups.

    Time frame: From W5 to W8 (4 weeks), W9 to W12 (4 weeks), and W5 to W12 (8 weeks)

  5. Compare the changes in WOMAC A1 score (walk-associated pain), WOMAC A, B and C score and patient global assessment (PTGA) at the 4th, 8th and 12th week from baseline between two groups.

    Time frame: At the 4th week from baseline (1 week), at the 8th week from baseline (1 week), and at the 12th week from baseline (1 week)

  6. Compare the changes in clinical observer global assessment (COGA), and scores for activities of daily living (ADL) at the 4th, 8th and 12th week from baseline between two groups.

    Time frame: At the 4th week from baseline (1 week), at the 8th week from baseline (1 week), and at the 12th week from baseline (1 week)

Other outcomes

  1. Incidence of all adverse events (AEs) and serious adverse events (SAEs)

    Time frame: up to 16 weeks

07

Study locations

2 of 6 sites recruiting
  • Peking Union Medical College Hospital
    Peking, Beijing 100730, China
    Active, not recruiting
  • The First Affiliated Hospital of Chongqing Medical University
    Chongqing, Chongqing 400016, China
    Not yet recruiting
    • Wei Huang, Doctor · Contact+86-13883383330
  • Nanfang Hospital
    Guangzhou, Guangdong 510515, China
    Recruiting
    • Zhanjun Shi, Doctor · Contact+86-13503037919
  • Nanjing Drum Tower Hospital
    Nanjing, Jiangsu 210008, China
    Not yet recruiting
    • Qing Jiang, Doctor · Contact+86-13605192953
  • The Second Affiliated Hospital of Xi'an Jiaotong University
    Xi'an, Shaanxi 409099, China
    Recruiting
  • Shanghai 6th People's Hospital
    Shanghai, Shanghai 200235, China
    Not yet recruiting
    • Changqing Zhang, Doctor · Contact+86-13003104089
08

Timeline

Tracking since Sep 25, 2026
Not marked actual or estimatedDates not marked actual or estimated

The record gives a start of Apr 2016, a primary completion of Oct 2017 and a completion of Dec 2017. It does not say whether these dates are actual or estimated.

How these figures are worked out, and which studies are left out of them.

Registered
Jun 27, 2016
First posted
Jul 7, 2016
Start
Apr 2016
Primary completionEst.
Oct 2017
CompletionEst.
Dec 2017
Last update
May 4, 2017
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on May 4, 2017, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
09

Registry details

Key details

Study ID
NCT02826031
Lead sponsor
Kunming Baker Norton Pharmaceutical Sales Co., Ltd.
Responsible party
Sponsor
First posted
Jul 7, 2016
Start date
Apr 2016
Primary completion
Oct 2017 (estimated)
Completion
Dec 2017 (estimated)
Last update
May 4, 2017

Study contacts

YA NAN TANG, Master
Contact
annie_tyn@163.com
+86-21-33278388 ext. 211
Kun Zheng WANG, Doctor
Contact
wkzh1955@163.com
+86-29-87678326
Kun Zheng WANG, Doctor
study chair · Second Affiliated Hospital of Xi'an Jiaotong University
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is status unknown, as verified in May 2017. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Hyaluronic Acid

Start the discussion